Group 1 - Orion Corporation has converted 141,959 A shares into B shares, with the conversion recorded on June 23, 2025 [1] - After the conversion, the total number of shares in Orion Corporation is 141,134,278, consisting of 32,308,783 A shares and 108,825,495 B shares [1] - The total number of votes for the company's shares after the conversion is 755,001,155 [1] Group 2 - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience, focusing on human and veterinary pharmaceuticals and active pharmaceutical ingredients [2] - In 2024, Orion's net sales reached EUR 1,542 million, and the company employed approximately 3,700 professionals globally [2] - The core therapy areas of Orion's pharmaceutical R&D include oncology and pain, with proprietary products developed for treating cancer, neurological diseases, and respiratory diseases [2]

Core Viewpoint - Teva Pharmaceutical Industries Ltd. has published its 2024 Healthy Future Report, highlighting its achievements in sustainability and access to medicines, which are integral to its long-term growth strategy [1][5]. Healthy People - Teva launched two new access to medicines programs, bringing the total to nine, exceeding its target of eight by 2025. The company donated approximately 18 million doses of medicine valued at $23 million and provided 2.2 million doses at low cost, benefiting 187,000 patients. Additionally, five programs focused on strengthening health systems and capacity building, aiding around 56,000 individuals [2]. Healthy Planet - Teva achieved a 29% reduction in absolute scope 1 and 2 greenhouse gas emissions from 2019 levels, surpassing its 25% target by 2025 ahead of schedule. Furthermore, 73% of applicable Teva sites met safe discharge levels for antibiotics, reducing environmental pollution. A pilot program in Germany educated over 65,000 healthcare professionals, resulting in approximately 389,000 patient interactions regarding appropriate antibiotic use [3][8]. Healthy Business - Teva emphasized integrity in operations, with over 99% of employees retrained on compliance and ethics, meeting its annual target. Additionally, 41% of significant suppliers were evaluated for sustainability performance, and all high-risk third-party partners underwent evaluation through Teva's Third-Party Due Diligence tool, promoting responsible sourcing practices [4][8]. Recognition and Impact - Teva received improved sustainability scores from organizations such as Sustainalytics, MSCI, and EcoVadis, along with awards for its programs and progress. The company's generic medicines contributed to $39.7 billion in savings for healthcare systems across 22 countries [5][8].

Group 1 - Orion Corporation has received a notification regarding transactions made by its board member, Karen Lykke Sørensen, under the Market Abuse Regulation [1] - The transaction involved the receipt of a share-based incentive, with a volume of 415 shares at a unit price of 0 EUR [1] - In 2024, Orion's net sales amounted to EUR 1,542 million, and the company employed approximately 3,700 professionals globally [2] Group 2 - Orion Corporation operates as a Nordic pharmaceutical company, developing, manufacturing, and marketing both human and veterinary pharmaceuticals [2] - The company has a diverse portfolio that includes proprietary and generic medicines, as well as consumer health products, focusing on oncology and pain in its pharmaceutical R&D [2] - Orion's shares are listed on Nasdaq Helsinki, indicating its presence in the public market [2]

Group 1 - Orion Corporation has received a notification regarding transactions made by its board member Kari Jussi Aho, specifically concerning share-based incentives [1] - The transaction occurred on April 30, 2025, involving 415 shares at a unit price of 0 EUR, indicating a receipt of a share-based incentive [1] - Orion Corporation is a Nordic pharmaceutical company with a history of over a hundred years, focusing on human and veterinary pharmaceuticals, and has a diverse portfolio including proprietary and generic medicines [2] Group 2 - In 2024, Orion's net sales reached EUR 1,542 million, and the company employed approximately 3,700 professionals globally [2] - The core therapy areas of Orion's pharmaceutical R&D include oncology and pain management, with proprietary products aimed at treating cancer, neurological diseases, and respiratory diseases [2] - Orion's shares are listed on Nasdaq Helsinki, indicating its presence in the public market [2]

Company Overview - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience in developing, manufacturing, and marketing human and veterinary pharmaceuticals and active pharmaceutical ingredients [2] - The company has a diverse portfolio that includes proprietary and generic medicines as well as consumer health products, focusing on oncology and pain as core therapy areas in its pharmaceutical R&D [2] - In 2024, Orion's net sales reached EUR 1,542 million, and the company employed approximately 3,700 professionals globally [2] Managerial Transactions - Eija Ronkainen, a member of the Board and Deputy member, made an initial notification regarding a transaction involving shares of Orion Corporation [1] - The transaction occurred on April 30, 2025, involving the receipt of a share-based incentive, with a volume of 415 shares at a unit price of 0 EUR [1] - The aggregated transaction also reported a volume of 415 shares with a volume-weighted average price of 0 EUR [1]

Group 1 - Orion Corporation has received a notification regarding transactions made by its board member Ari Lehtoranta, specifically concerning share-based incentives [1] - The transaction occurred on April 30, 2025, involving 508 shares at a unit price of 0 EUR, indicating a receipt of a share-based incentive [1] - Orion Corporation's net sales for 2024 amounted to EUR 1,542 million, and the company employs approximately 3,700 professionals globally [2] Group 2 - Orion Corporation operates as a Nordic pharmaceutical company with a focus on developing, manufacturing, and marketing both human and veterinary pharmaceuticals [2] - The company has a diverse portfolio that includes proprietary and generic medicines, as well as consumer health products, with core therapy areas in oncology and pain [2] - Orion's shares are listed on Nasdaq Helsinki, indicating its presence in the public market [2]

Group 1 - Orion Corporation has received a notification regarding transactions made by its board member Henrik Stenqvist, specifically related to share-based incentives [1] - The transaction occurred on April 30, 2025, involving 415 shares at a unit price of 0 EUR, indicating a receipt of a share-based incentive [1] - Orion Corporation's net sales in 2024 amounted to EUR 1,542 million, and the company employs approximately 3,700 professionals globally [2] Group 2 - Orion Corporation operates as a Nordic pharmaceutical company with a focus on developing, manufacturing, and marketing both human and veterinary pharmaceuticals [2] - The company has a diverse portfolio that includes proprietary and generic medicines, as well as consumer health products, with core therapy areas in oncology and pain [2] - Orion's shares are listed on Nasdaq Helsinki, indicating its presence in the public market [2]

Group 1 - Orion Corporation has received a disclosure regarding transactions made by its board member Veli-Matti Mattila under Market Abuse Regulation [1] - The transaction involved the receipt of a share-based incentive, with a volume of 830 shares at a unit price of 0 EUR [1] - The aggregated transaction also reflects a volume of 830 shares with a volume weighted average price of 0 EUR [1] Group 2 - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience, focusing on human and veterinary pharmaceuticals [2] - In 2024, Orion's net sales reached EUR 1,542 million, and the company employed approximately 3,700 professionals globally [2] - Orion's core therapy areas in pharmaceutical R&D include oncology and pain, with proprietary products developed for treating cancer, neurological diseases, and respiratory diseases [2]

Core Insights - Orion Corporation has reported a transaction involving Hilpi Rautelin, a member of the Board, who received a share-based incentive on April 30, 2025 [1] - The transaction involved 508 shares with a unit price of 0 EUR, indicating a non-monetary incentive [1] Company Overview - Orion Corporation is a Nordic pharmaceutical company with over a century of experience in developing, manufacturing, and marketing pharmaceuticals and active pharmaceutical ingredients [2] - The company focuses on oncology and pain management in its pharmaceutical R&D, with proprietary products aimed at treating cancer, neurological diseases, and respiratory diseases [2] - In 2024, Orion's net sales reached EUR 1,542 million, and the company employed approximately 3,700 professionals globally [2] - Orion's shares are listed on Nasdaq Helsinki, comprising both A and B shares [2]

ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MAY 2025 at 11.45 EEST Orion Corporation: Managers’ transactions – Maziar Mike Doustdar Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Maziar Mike D ...